Filing Flows › Pacific Biosciences of California (PACB) › R&D spending
Pacific Biosciences of California (PACB) R&D spending by quarter
Pacific Biosciences of California's R&D spending was $20.2M in Q3 2026 (third quarter 2026), -12% from Q2 2026. Over the last 6 quarters it ranged from $20.2M (Q3 2026) to $29.1M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $20.2M | -12% | -11% |
| Q2 2026 | $23.0M | +0.6% | +2% |
| Q4 2025 | $22.9M | +0.1% | — |
| Q3 2025 | $22.8M | +1% | — |
| Q2 2025 | $22.5M | -22% | — |
| Q1 2025 | $29.1M | — | — |
Q3 2026 at a glance
Pacific Biosciences of California, Q3 2026: revenue $40.6M (+6% year over year), operating margin -91.2%, net loss $37.8M, operating cash flow −$37.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pacific Biosciences of California's R&D spending?
Pacific Biosciences of California's R&D spending was $20.2M in Q3 2026 (third quarter 2026), -12% from Q2 2026.
How has Pacific Biosciences of California's R&D spending changed?
Over the last 6 quarters it ranged from $20.2M (Q3 2026) to $29.1M (Q1 2025).
Q3 2026 results → · How Pacific Biosciences of California makes money →